ascopubs.org5d
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...
ascopubs.org5d
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...
ascopubs.org5d
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ascopubs.org5d
A survival prediction model for veterans with advanced bladder cancer (BC) treated with immune checkpoint inhibitors (ICI).
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer. PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting ...
ascopubs.org5d
Checkpoint blockade as neoadjuvant strategy: A single-arm meta-analysis of dual PD-1/PD-L1 and CTLA-4 inhibition in urothelial cancer.
Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis. Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients ...
ascopubs.org5d
Real-world prevalence and outcomes of androgen receptor ligand-binding domain mutations in prostate cancer.
Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC). Evaluating the association between bone pain and radiologic progression-free survival (rPFS) ...
ascopubs.org4d
Protein analysis of urachal carcinoma tissue based on different antibody-drug conjugate therapeutic targets.
CD39 expression as a predictive biomarker for neoadjuvant treatment in muscle-invasive bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...
ascopubs.org5d
Impact of PSMA-PET and conventional imaging on contemporary management in patients with biochemical recurrence after radical prostatectomy.
Utilizing ChatGPT for assessing disease volume in patients (pts) with metastatic prostate cancer (mPC). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...
ascopubs.org10d
Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
ascopubs.org5d
Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: A phase II trial.
Cardiovascular mortality risk in primary penile cancer patients: A retrospective cohort study from 2000 to 2021. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.
ascopubs.org5d
Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.
Deciphering immune-genomic markers of hyperprogression in patients (Pts) with metastatic urothelial cancer (mUC) treated with immune checkpoint inhibitors (ICIs). This is an ASCO Meeting Abstract from ...
ascopubs.org5d
The comparison of clinical utility between pan-cancer panel and PCa-specific panel for mCRPC.
Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy. Barriers to ...